Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease-Reference-Cited by-同舟云学术

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

Published:2014-07-28 Issue:3 Volume:4 Page:337-344
ISSN:1877-7171
Container-title:Journal of Parkinson's Disease
language:
Short-container-title:JPD

Author:

Aviles-Olmos Iciar¹,Dickson John²,Kefalopoulou Zinovia¹,Djamshidian Atbin³,Kahan Joshua¹,Ell Peter²,Whitton Peter⁴,Wyse Richard⁵,Isaacs Tom⁵,Lees Andrew³,Limousin Patricia¹,Foltynie Thomas¹

Affiliation:

1. Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK

2. Department of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK

3. Reta Lila Weston Laboratories, London, UK

4. UCL School of Pharmacy, London, UK

5. The Cure Parkinson’s Trust, St. Botolph’s, London, UK

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Cited by 227 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease;European Journal of Pharmacology;2024-11

2. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study;Movement Disorders;2024-08-27

3. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?;Neuropharmacology;2024-08

4. GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice;Neuropharmacology;2024-07

5. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative;Journal of Parkinson's Disease;2024-06-04